Header Logo

Connection

Dongfeng Qu to Epithelial-Mesenchymal Transition

This is a "connection" page, showing publications Dongfeng Qu has written about Epithelial-Mesenchymal Transition.
  1. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget. 2015 Feb 10; 6(4):2193-205.
    View in: PubMed
    Score: 0.117
  2. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014 Oct 15; 5(19):9269-80.
    View in: PubMed
    Score: 0.115
  3. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
    View in: PubMed
    Score: 0.036
  4. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer. 2017 02 01; 16(1):30.
    View in: PubMed
    Score: 0.034
  5. Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. Cancer Res. 2016 07 15; 76(14):4090-9.
    View in: PubMed
    Score: 0.032
  6. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014 Aug 28; 351(1):151-61.
    View in: PubMed
    Score: 0.028
  7. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One. 2013; 8(9):e73940.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.